Skip to main content

Table 3 Overall survival within each treatment arm by baseline biomarker levels dichotomized at the median

From: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma

Plasma Biomarker

Overall Survival

Pinteraction

Cabozantinib

Everolimus

Median OS, mo

HR (95% CI)

Median OS, mo

HR (95% CI)

≥median

biomarker

<median biomarker

≥median biomarker

<median biomarker

CA9

21.4

22.0

1.19 (0.85, 1.68)

15.4

16.5

1.20 (0.89, 1.62)

0.99

HGF

15.4

NR

2.79 (1.92, 4.05)*

13.0

19.4

1.78 (1.32, 2.42)*

0.08

MET

19.9

NR

1.29 (0.91, 1.81)

15.0

18.9

1.42 (1.05, 1.91)*

0.70

GAS6

17.2

NR

2.01 (1.41, 2.86)*

13.9

18.4

1.42 (1.05, 1.92)*

0.14

AXL

18.7

22.0

1.48 (1.05, 2.09)*

16.4

16.5

1.00 (0.74, 1.35)

0.11

VEGF

16.1

NR

2.16 (1.51, 3.08)*

14.9

18.4

1.43 (1.06, 1.94)*

0.09

VEGFR2

21.4

22.0

0.97 (0.69, 1.36)

16.5

16.4

0.90 (0.66, 1.21)

0.75

IL-8

17.2

NR

1.90 (1.34, 2.68)*

13.0

19.4

1.78 (1.31, 2.42)*

0.73

  1. Hazard ratios are for high (≥median) versus low (<median) biomarker levels. P-interaction was obtained from a separate model that included the interaction between treatment and biomarker level
  2. NR not reached
  3. * p < 0.05 for the analysis
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us